Skip to content
Open access

A Tumor-Microenvironment-Responsive Chemically Masked IL‑2 Prodrug Potentiates PD‑1 Checkpoint Blockade and Elicits Robust Antitumor Efficacy

Aug 2026 · ACS Central Science · Vol 12, pp. 1223 - 1236 · 0 citations · 48 references
Medicine

TL;DR

A chemically masked IL-2 prodrug (Cm-proIL2) that enables tumor-microenvironment-responsive cytokine activation through tumor-associated protease cleavage to demonstrate the feasibility of chemically masked, tumor-responsive cytokine activation as a strategy for improving the therapeutic index of IL-2-based immunotherapies.

Abstract

Interleukin-2 (IL-2) is a potent mediator of T-cell activation with significant potential for cancer immunotherapy, yet its clinical utility is severely constrained by its narrow therapeutic window. Here we report a chemically masked IL-2 prodrug (Cm-proIL2) that enables tumor-microenvironment-responsive cytokine activation through tumor-associated protease cleavage. Site-specific conjugation of a poly(ethylene glycol) (PEG) moiety selectively masks peripheral receptor engagement, while PEG removal within the tumor microenvironment restores IL-2 receptor binding and reduces molecular size, thereby enhancing intratumoral lymphocyte penetration and effector T cell functionality. Building on this modular platform, we further engineered a PD-1-targeted nanobody fusion, PD1-Cm-proIL2, to enable the cis delivery of IL-2 activity to PD-1+ tumor-infiltrating T cells. PD1-Cm-proIL2 induces robust antitumor immunity, resulting in complete tumor regression and durable protection upon tumor rechallenge in a murine colorectal cancer model. Together, these findings demonstrate the feasibility of chemically masked, tumor-responsive cytokine activation as a strategy for improving the therapeutic index of IL-2-based immunotherapies.

Read PDF

Similar papers

Open access Aug 2026

αHSA-proIL-12: A Tumor-Conditional IL-12 Prodrug with Reduced Systemic Toxicity and Potent Antitumor Activity

Interleukin-12 (IL-12) potently promotes the recruitment and activation of immune cells within the tumor microenvironment (TME), highlighting its immense potential for cancer therapy. However, its dose-limiting systemic toxicity and short half-life severely hinder its clinical translation. Here, we design a tumor-condi...

Xi Wang, Liu Yang, Yu-Hao Hou et al. · 0 citations
Open access Sep 2026

IL-2/CD25 acts within the tumor microenvironment to reprogram tumor-specific cytotoxic CD8+ T cells while restraining regulatory T-cell accumulation

Abstract Background Targeting the high-affinity interleukin-2 receptor (IL-2R) on CD8+ T effector cells elicits potent antitumor responses that are augmented when co-administered with programmed cell death protein 1 (PD-1) blockade. Methods Using the mouse IL-2/CD25 fusion protein (mIL-2/CD25) at a high dose (HD) and a...

Kathryn M. Laporte, Janika Põder, D. Ivanova et al. · 0 citations
Open access Sep 2026

Tumor-targeted IL-10 synergizes with IL-2 to enhance antitumor immunity while minimizing immune-related adverse events

Tumor-targeting cytokines have emerged as a promising strategy for cancer immunotherapy, although their mechanisms of action often remain complex. In this study, we develop an approach by combining tumor-targeted IL-10 (CmAb-(IL10)2) with IL-2 (CmAb-IL2) to enhance antitumor immunity while minimizing immune-related adv...

Zhi-Chen Sun, Yi-Fei Hu, Casey Moore et al. · 0 citations
Sep 2026

TGF-β-Targeting Platinum(IV) Prodrugs Remodel Tumor Microenvironment of Pancreatic Cancer via Antifibrotic and Immunomodulatory Effects.

Pancreatic ductal adenocarcinoma (PDAC) features dense desmoplastic stroma that impedes drug penetration and immune infiltration, and promotes therapeutic resistance. As a central driver of stromal fibrosis and immunosuppression, TGF-β represents an attractive target for overcoming these barriers. Herein, we report nov...

Zhe Li, Xiao-Meng Liu, Xiao-Ya Wang et al. · 0 citations
Open access Oct 2026

A reciprocally masked anti-CD47/IL-2 fusion protein promotes antitumor immunity and limits systemic toxicity.

Cancer immunotherapies have achieved meaningful clinical benefit but remain limited by systemic toxicities that restrict the use of potent immune modulators. CD47-targeting antibodies promote tumor cell phagocytosis but are hindered by hematologic toxicity, while IL-2 activates cytotoxic lymphocytes but induces broad,...

Elise Léchine, Laura Cons, L. Garnier et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.